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Abstract A population pharmacokinetic analysis was
conducted to characterize the pharmacokinetics of fexo-
fenadine in Japanese pediatric patients (6 months through
16 years) with perennial allergic rhinitis or atopic derma-
titis. The dataset was composed of 515 patients (including
109 adults), for a total of 1,080 concentration–time points.
The analysis was performed with NONMEM using the
SAEM method. Several structural models and residual
error models were evaluated. The relationship between the
individual estimates and the potential covariates was then
investigated: demographic and pathophysiologic charac-
teristics were tested as potential model covariates (forward
selection method). The qualification of the model was
performed using visual predictive check and bootstrap. A
two-compartment disposition model with first-order
absorption best fitted the data. The inter-individual vari-
ability was modeled through an exponential error model for
all parameters (except for ka for which no inter-individual
term could be estimated), while a proportional error model
was used to model the residual variability. The final model
included two covariates on elimination clearance and one
on the intercompartmental clearance. CL/F was related to
BSA and patient’s age (expressed in months) Q/F was also
related to BSA. Once the model was correctly qualified,
exposure parameters such as Cmax and AUCs were com-
puted and compared between each age sub-group and
between Japanese and Caucasians patients. These com-
parisons did not reveal any major difference (less than
50 %) between subgroups.
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Introduction
Fexofenadine HCl (Allegra) is an antihistamine with
selective peripheral H1-receptor antagonist activity devel-
oped for allergic diseases. In Japan, it was approved for the
indications of allergic rhinitis, urticaria and pruritus asso-
ciated with skin diseases (eczema/dermatitis, pruritus
cutaneous, atopic dermatitis). It is marketed at recom-
mended doses of 60 mg twice daily for adults and children
aged 12 years or older and 30 mg twice daily for children
aged 7–11 years.
From studies in adults, fexofenadine appears to be rap-
idly absorbed after single or multiple oral administrations
with a maximum plasma concentration observed 1–3 h
after dosing. The absolute bioavailability is estimated to be
at least 33 %. The apparent volume of distribution is large
(5.4–5.8 L/kg) and the plasma protein binding is around
60–70 %. Fexofenadine is poorly metabolized (5 % of the
total oral dose) and is mainly excreted in faeces via biliary
excretion (80 and 11 % of the total dose in faeces and in
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urine, respectively). The apparent total body clearance is
48–58 L/h [1]. Fexofenadine is a probe substrate for the
efflux transporter P-glycoprotein (P-gp) and for various
uptake transporters, including human hepatic OATPB3; it
is neither an inducer nor inhibitor of transporter activity at
therapeutic doses [2]. In a previous pharmacokinetic (PK)
study [3] conducted on 213 patients (77 children aged from
6 months to 12 years and 136 adults), race was explored
and did not show any impact on the PK of fexofenadine.
A dry syrup formulation was developed to facilitate
dosing of Allegra in the pediatric Caucasian population.
To evaluate this dry syrup formulation (15 and 30 mg
twice daily doses) in Japanese pediatric patients 6 months
through 11 years of age, two Phase III studies were con-
ducted. Exposures were to be computed and compared to
those of Caucasians to verify the proposed dose adjust-
ment. As the number of samples collected per patient was
limited in these studies (one or two samples), the Popula-
tion Pharmacokinetic (PopPK) technique was used to
characterize the PK of fexofenadine in this population and
to compute individual patients’ exposures.
While some PopPK analyses have already been made on
Caucasian patients [3], this analysis is the first one per-
formed on Japanese pediatric patients. This paper presents
the results of this PopPK model. In a second step, indi-
vidual patients’ exposures computed from this model are
compared between the different dosing groups to show the
similarity of pediatrics’ exposures to adults’ ones, hence
demonstrating the appropriateness of the proposed dosing
algorithm, established on the basis of patients’ age and
weight. Results of Japanese patients are finally compared
with those of Caucasians, as described in the paper from
Krishna et al. [3].
Materials and methods
Study design
Two open-label, uncontrolled 4-week studies were con-
ducted in pediatric patients: one in the treatment of
perennial allergic rhinitis, the other one in patients with
atopic dermatitis, for a total of 210 Japanese patients from
6 months to 11 years (381 concentrations–time points).
The dosage of fexofenadine, given as a dry syrup formu-
lation, was 15 mg twice daily for pediatric patients aged
from 6 months up to less than 2 years, and older than
2 years but weighing less than 10.5 kg, and 30 mg twice
daily for pediatric patients 2–11 years of age. Two blood
samples per patient have been performed for determination
of plasma fexofenadine concentrations: one at week 2 and
one at week 4. Data from a previous PopPK analysis were
also added: in this previous analysis, 298 Japanese patients
aged from 7 to more than 16 years (594 concentrations-
time points) were included. The dosage of fexofenadine,
given as tablets, was 30 mg twice daily for 8 days for
7–11 years, and 60 mg twice daily for 8 days for 12 years
or more. Two blood samples per patient were performed
after the morning dose of the study drug on day 8:3 h after
administration and 3–9 h after administration. Data from
seven healthy Japanese volunteers (105 concentration–time
points) obtained after 7-day twice-daily repeated dosing of
60 mg fexofenadine were also included. Overall, the total
data set was composed of 515 subjects, for a total of 1,080
fexofenadine plasma concentrations (ranging from 1.2 to
6096 ng/mL). Demographic characteristics of the patients
are presented in Table 1.
The clinical studies were conducted complying with the
Declaration of Helsinki and related Japanese regulatory
guidelines. The studies were initiated and conducted after
getting an approval of the institutional ethical committee at
each institute. Due to the age of the patients, the informed
consent was obtained from the parents or the legal
representative.
Model building
The PopPK analysis was performed with the NONMEM
[4] computer program (version 7.1.2) running on a LI-
NUX cluster of multi-processor computers [5]. The First
Order Conditional Estimation (FOCE) and the Stochastic
Approximation of the Expectation–Maximization (SAEM)
methods were evaluated; SAEM was selected for the model
building process, as it was found to be the most stable
method: the covariance step was difficult to obtain with
FOCE.
Selection of the pharmacostatistical model
Initially the population parameters describing the PK
model were estimated without covariate effects. Different
structural PK models (one- and two-compartment disposi-
tion models with first order absorption) and different error
models (additive, proportional and combined) were eval-
uated to describe residual variability. The full non diagonal
matrix (x block) and the different combinations of g cor-
relations and gs fixed to zero were evaluated.
Covariates inclusion
The influence of potential covariates was assessed. The
baseline values of age (in months), body weight (WGT),
body surface area (BSA) and creatinine clearance (CLcr)
were tested as continuous potential covariates, together with
dose and plasma levels of alanine aminotransferase (ALT),
alkaline phosphatase (ALK), aspartate aminotransferase
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(AST), lactate dehydrogenase (LDH), total bilirubin (TBIL)
and total protein (TPRO). Sex and study were tested as
categorical variables. All potential covariates were added
individually to the model (forward selection method).
Covariates effects were introduced into the population
model using different functions: linear, power, exponential
and allometric function. For the allometric functions,
covariate effects were fixed (with 0.75 exponent for clear-
ance and one for volume) and centered with 70 as recom-
mended for pediatric data [6–8], or centered with the
median weight value of the population. All the functions
were tested at each step of the building model. A decrease of
objective function value (OFV) of at least 3.84, associated
with a P value \0.05 with one degree of freedom, was
required and a decrease in the interindividual variability of
the pharmacokinetic parameters and in r value (which
summarizes the unexplained variability on the estimated
pharmacokinetic parameters) was expected.
In a last step, both individual and population parameters
were re-estimated considering the relationship with the
covariates. Each accepted covariate was deleted in turn from
the proposed final model (backward elimination). An
increase in OFV of at least 10.8, associated with a P-value
\0.001 with one degree of freedom, was required for sta-
tistical significance to account for multiple testing and the
large dataset and hence for the re-inclusion of the covariate.
Model validation
At each step of the model building process (i.e., each
step of the pharmacostatistical model building and
refinement, and each step of the covariate model build-
ing), GoF plots were used to evaluate the quality of the
PopPK model. Several acceptance criteria (successful
minimization of the algorithm, covariance phase com-
pleted without any warning message, significant digit
greater than three, no correlation between parameter
estimates larger than 0.95 and relative standard error
[%RSE] lower than 50 %) were to be reached to con-
sider the model as acceptable.
Bootstrap
The robustness of the model and the accuracy of parame-
ters estimates (standard error computation) were assessed
using a bootstrap method [9]. The entire procedure was
undertaken in an automated fashion. From the original
dataset of n patients, 500 bootstrap sets of n individuals
were drawn with replacement (re-sampling). For each of
the 500 bootstrap sets, the PopPK parameters were esti-
mated. With the 500 estimates of each PopPK parameter,
the corresponding mean, median, standard deviation, 2.5
and 97.5th percentiles were estimated.
Table 1 Demographic characteristics (baseline values) of the patients included in the population pharmacokinetic analysis
Covariate or characteristic Total
dataset
Infants
\2 Years
Children C2
to \7 Years
Children C7
to \12 Years
Adolescents C12
to \16 Years
Adults
C16 Years
Mean (SD) values
Age (years) 14.1 (13.8) 0.564 (0.501) 4.26 (1.37) 9.00 (1.31) 13.2 (1.13) 37.2 (12.6)
Body weight (Kg) 35.8 (18.9) 9.25 (1.85) 17.3 (3.79) 30.9 (7.94) 50.8 (12.7) 57.2 (11.4)
Body surface area (m2) 1.14 (0.429) 0.420 (0.0619) 0.704 (0.111) 1.07 (0.162) 1.49 (0.214) 1.61 (0.183)
Aspartate aminotransferase (UI/L) 22.6 (12.1) 41.3 (13.5) 28.4 (4.75) 19.0 (7.01) 15.9 (6.73) 20.4 (14.2)
Alanine aminotransferase (UI/L) 19.8 (7.90) 22.3 (11.3) 13.8 (5.69) 20.1 (7.29) 21.6 (4.57) 20.9 (8.54)
Alcaline phosphatase (UI/L) 573 (371) 0 (0) 720 (151) 835 (206) 724 (357) 202 (57.0)
Lactate dehydrogenase (UI/L) 225 (58.2) 309 (55.3) 252 (37.1) 232 (41.0) 200 (41.6) 173 (42.4)
Bilirubin (lmol/L) 8.75 (4.91) 5.08 (2.15) 5.04 (1.81) 7.76 (3.01) 11.5 (4.63) 12.5 (6.08)
Total protein (UI/L) 64.2 (22.8) 0 (0) 71.0 (4.18) 72.0 (6.73) 72.1 (3.88) 72.1 (4.19)
Creatinine (lmol/L) 40.3 (15.9) 17.1 (2.73) 27.0 (5.26) 37.9 (6.60) 49.2 (10.2) 57.8 (14.5)
Creatinine clearance (mL/min) 171 (43.0) 211 (35.3) 195 (31.0) 176 (27.7) 179 (32.9) 116 (30.8)
Number of patients (%)
Phase III study #1 (%) 108 (21.0 %) 7 (12.7 %) 50 (61.7 %) 51 (29.5 %) – –
Phase III study #2 (%) 102 (19.8 %) 48 (87.3 %) 31 (38.3 %) 23 (13.3 %) – –
Previous PopPK study (%) 305 (59.2 %) – – 99 (57.2 %) 97 (100 %) 109 (100 %)
Males 276 (53.6 %) 30 (54.5 %) 54 (66.7 %) 99 (57.2 %) 59 (60.8 %) 34 (31.2 %)
Females 239 (46.4 %) 25 (45.5 %) 27 (33.3 %) 74 (42.8 %) 38 (39.2 %) 75 (68.8 %)
Japanese (%) 514 (99.8 %) 55 (100 %) 80 (98.8 %) 173 (100 %) 97 (100 %) 109 (100 %)
Non Japanese (%) 1 (0.194 %) – 1 (1.23 %) – – –
Total number of patients 515 55 81 173 97 109
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Visual predictive check
The visual predictive check (VPC) [10] and the prediction
corrected visual predictive check (pcVPC) [11], which is more
suitable to data following adaptative designs such as dose
adjustments, were used to evaluate the performance of the final
model. These approaches, based onsimulations from the model
and the underlying design of the observed data, are a graphical
comparison between the observed data and prediction intervals
derived from the simulated data. In pcVPC, the dependent
variable was prediction corrected: the variability coming from
binning across independent variables was removed by nor-
malizing the observed and simulated dependent variable based
on the typical population prediction for the median indepen-
dent variable in the bin. The pcVPC was used to evaluate the
performance of the final model at steady state as a function of
time (in both linear and logarithmic scales) but also as a
function of the covariates included in the PopPK model.
Computation of individual exposures
From the population parameters, individual PK parameters,
single dose and steady state exposure parameters (maxi-
mum [Cmax, Cmax,ss] and minimum [Cmin, Cmin,ss] con-
centrations, and area under the concentration–time curve
between two drug intakes [AUCs, AUCs,ss]) were estimated
for each patient. Exposure variables were then plotted
given the covariates included in the model to evaluate the
magnitude of the covariate effect and compared to values
observed in adults. Comparisons were also performed with
Caucasian patients [3].
Results
Population model
The pharmacostatistical model was a two-compartment dis-
position model parameterized in terms of an absorption
constant (ka, 1/h) characterizing the first-order absorption
process from the depot to the central compartment, which
was described by an apparent distribution volume Vc/F(L).
The peripheral compartment was related to the central one by
an inter-compartmental clearance Q/F (L/h) and described by
an apparent distribution volume Vp/F(L). The elimination
process from the central compartment was defined by an
elimination clearance CL/F (L/h). The inter-individual vari-
ability was modeled through an exponential model for all
parameters (except for ka for which no inter-individual term
could be provided), while a proportional error model was
used to model the residual variability. Three covariates sig-
nificantly decreased the objective function and the interin-
dividual variability of the PK parameters:
(i) CL/F was related to BSA and patient’s age
(expressed in months) according to: CL/F =
h2 BSA1:124
 h6 AGEðmonthsÞ
h8 + AGE (months)
, where 1.124
is the median BSA value in the dataset,
(ii) Q/F was also related to BSA according to: Q/F =½
h3 BSA1:124
 h7 ,
(iii) Vc/F was related to weight according to: Vc
F
¼
h4  WGT70
 
.
For Vp/F, no relationship with any covariate led to a
significant decrease of OFV. The backward deletion per-
formed in the last step of the model development process
led to WGT covariate deletion (iii) from the full model.
The final PopPK parameters and their relationship to
covariates are presented in Table 2, together with the
model parameters obtained before covariates’ inclusion.
The relationship between individual estimates of CL/F and
covariates retained in the model are given in Fig. S1 in
Supplementary material.
Validation of the model
All the acceptance criteria were reached.
Computation of standard error of estimates using bootstrap
The robustness of this final model and the accuracy of
parameter estimates (standard error computation) were
assessed using a bootstrap method. The bootstrap was
performed on the total data set using the parameters of the
final model as initial estimates. From the total data set (i.e.,
515 patients), 500 runs were launched and 480 successful
runs (96 %) were obtained. For each successful run, the
PopPK parameters were estimated and the corresponding
mean, standard deviation, 2.5 and 97.5th percentiles were
estimated for each parameter. The median parameter esti-
mates obtained from these bootstraps were similar to those
of the final PopPK parameters (Table 2).
Visual predictive check
The VPC and pcVPC were used to evaluate the perfor-
mance of the final model at steady state. The results of the
simulations performed for pcVPC (one thousand samples
time by patients) are presented in Fig. 1 and revealed a
good predictive ability of the model.
Computation of individual pharmacokinetic parameters
Once the model validated using the previously described
approaches, individual PK parameters (CL/F, Vc/F, Q/F
and Vp/F), single dose and steady state exposure variables
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(Cmax, Cmax,ss, Cmin, Cmin,ss, AUCs and AUCs,ss) were
estimated for each patient. Main descriptive statistics in the
different subpopulations are given in Table 3 as a function
of the covariates included in the model. As an illustration,
AUCs,ss are represented in Fig. 2. Similar trends were
observed with Cmax,ss and Cmin,ss.
Discussion
The population model developed in this analysis accurately
predicted fexofenadine plasma concentrations observed in
Japanese pediatric patients suffering of perennial allergic
rhinitis or atopic dermatitis. The available potential sources
of variability on the population parameters were exten-
sively investigated.
Two covariates were included in the model on CL/F and
Q/F: BSA and age (in months) were included on CL/F,
BSA was also included on Q/F. This inclusion allowed an
important decrease of the unexplained interindividual
variability on both clearances (from 49.1 to 28.3 % for CL/
F and from 66.0 to 41.4 % for Q/F) but also on the two
distribution volumes. No covariate was included on Vc/F,
Vp/F and ka.
In the paper of Krishna et al. [3], body weight was
identified as a significant covariate of the model. In the
current analysis, the OFV decrease was systematically
more important after inclusion of BSA rather than body
weight. As the main aim of the current study was to esti-
mate as accurately as possible individual exposures, the
covariate which allowed the better fit to the available data,
i.e., BSA, was kept in the final model. As BSA is directly
derived from body weight using the Dubois and Dubois
[12], formula the impact of body weight is integrated in
BSA.
In the end, the ‘body size’ measurement selected is of
minor importance: while the dosing algorithm used in these
clinical studies was adapted from the one proposed in
Caucasians on the basis of age and body weight (but Jap-
anese patients aged 0.5–2 years received only 15 mg dose
whatever their body weight), fexofenadine dosage will
finally be marketed without any dose adjustment to either
body weight or BSA. Dose is only adjusted according to
patient’s age in Japanese patients. The absence of side
Table 2 Population pharmacokinetic parameters obtained before and after covariates inclusion
Parameter No covariates Final model with covariates Bootstrap on final modela
Estimate %RSE Estimate %RSE [95 % CI] Median estimate [95 % CI]
Typical value of CL/F (h2, L/h)
b 38.9 3.00 44.8 3.48 [41.7; 47.9] 44.8 [42.1; 48.4]
Effect of BSA on CL/F (h6)
b NA NA 0.649 12.6 [0.485; 0.812] 0.647 [0.479; 0.788]
Effect of age on CL/F (h8)
b NA NA 7.33 36.1 [2.04; 12.6] 7.38 [3.25; 14.3]
Typical value of Vc/F (h1, L) 15.3 24.2 26.3 16.4 [17.7; 34.9] 27.0 [16.5; 37.6]
Typical value of Q/F (h3, L/h) 5.85 11.4 8.25 8.51 [6.85; 9.66] 7.70 [5.93; 10.5]
Effect of BSA on Q/F (h7)
c NA NA 1.60 12.2 [1.21; 1.99] 1.58 [1.14; 2.10]
Typical value of Vp/F (h4, L) 221 39.6 185 17.1 [122; 249] 190 [127; 331]
Typical value of ka (h5, 1/h) 0.272 0.660 0.280 1.36 [0.273; 0.288] 0.276 [0.262; 0.310]
Estimate (CV%) %RSE Estimate (CV%) %RSE [95 % CI] (Shrinkage %) Median estimate [95 % CI]
Inter-individual variability
xCL/F
2 0.241 (49.1) 12.0 0.0798 (28.3) 15.9 [0.0545; 0.105] (26.7) 0.0801 [0.0571; 0.107]
xVc/F
2 2.95 (172) 16.6 1.25 (112) 21.7 [0.708; 1.79] (55.3) 1.28 [0.818; 2.19]
xQ/F
2 0.435 (66.0) 33.5 0.172 (41.4) 9.90 [0.138; 0.206] (82.7) 0.155 [0.0378; 0.416]
xVp/F
2 0.561 (74.9) 38.8 0.350 (59.2) 19.2 [0.216; 0.485] (90.0) 0.310 [0.114; 0.715]
xka
2 Fixed to 0.00001
Residual variability
r2 0.131 (36.2) 7.55 0.139 (37.3) 7.00 [0.119; 0.158] (18.3) 0.138 [0.120; 0.158]
h and x are the PopPK parameters (h) and the variance of their associated inter-individual variability (x), r is the associated variance of the
residual (intra-individual) error variable (e)
F bioavailability, %RSE percentage of relative standard error (100 % * SE/Estimate), NA not applicable, 95 % CI 95 % confidence interval
a Bootstrap results obtained on 480 successful runs
b The expression of clearance including covariates effects is: CL/F = h2 BSA1:124
 h6 AGEðmonthsÞ
h8 + AGE (months)
c The expression of the intercompartmental clearance including covariate effect is: Q/F ¼ h3  BSA1:124
 h7
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effects, linked to the wide safety range of fexofenadine,
confirmed this selected dosing regimen.
All %RSEs were lower than 20 % (except the age effect
on clearance which was about 36 %). Probably due to the
very sparse data available (only two samples per patient for
the pediatric population), high values of g-shrinkage were
observed (26.7–90.0 %). r-shrinkage remained below 20 %.
Individual derived exposure variables estimated from
the PopPK model were similar in infants \2 years
receiving 15 mg twice daily, in children C2 to \7 years
receiving 30 mg twice daily, in adolescents’ C12 to
\16 years and in adults C16 years receiving 60 mg twice
daily. Exposure variables were approximately 35 % lower
in children C7 to \12 years receiving 30 mg twice daily
according to CL/F values.
The comparison of the PopPK parameters obtained in
Japanese and Caucasian children was only possible for
individual values of elimination clearance and Cmax
Fig. 1 Prediction corrected
visual predictive check as a
function of time (upper left:
linear scale, upper right: log
scale) or of covariates included
in the PopPK model (middle
left: BSA [linear scale], middle
right: BSA [log scale], lower
left: age [linear scale], lower
right: age [log scale]). Lines are
5, 50 and 95th percentiles of
observations, areas are 95 %
confidence intervals of these
percentiles
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Table 3 Mean (CV%) values of individual steady state exposures given by covariates included in the model
AUCs,ss (ng.h/mL) Cmax,ss (ng/mL) Cmin,ss (ng/mL)
15 mg dose (n = 56)
By age
Infants \2 years (n = 55) 1,090 (46.2) 155 (39.5) 34.4 (112)
Children C2 to \7 years (n = 1) 703a 111a 15.2a
By BSA
BSA B1.1249b m2 (n = 56) 1,080 (46.3) 154 (39.5) 34.0 (112)
BSA [1.1249b m2 No patient in this group
30 mg dose (n = 253)
By age
Children C2 to \7 years (n = 80) 1,060 (24.3) 176 (27.9) 25.8 (38.8)
Children C7 to \12 years (n = 173) 710 (19.8) 127 (21.4) 16.7 (30.2)
By BSA
BSA B1.1249b m2 (n = 199) 875 (28.1) 151 (28.3) 20.8 (41.1)
BSA [1.1249b m2 (n = 54) 621 (17.1) 112 (20.2) 15.1 (26.9)
60 mg dose (n = 206)
By age
Adolescents C12 to \16 years (n = 97) 1,150 (23.0) 213 (19.8) 28.4 (35.2)
Adults C16 years (n = 109) 1,110 (28.2) 200 (19.3) 29.2 (48.3)
By BSA
BSA B1.1249b m2 (n = 3) 1,280 (12.4) 239 (22.6) 28.2 (15.9)
BSA [1.1249b m2 (n = 203) 1,130 (25.9) 206 (19.7) 28.8 (43.0)
a Individual values
b Median of the dataset
Fig. 2 AUCs,ss as a function of covariates included in the population pharmacokinetic model
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obtained after single dose (Table 4), as results obtained in
Caucasian children [3] do not provide any value for volume
of distribution and steady state exposures. For these com-
parisons, Cmax values for Japanese children obtained after
administration of 15, 30 or 60 mg were converted in a
linear manner to the 80 mg dose for which they were
provided in [3].
As shown in Table 4, Cmax values were 40 % higher in
Caucasian than Japanese in children aged 0.5–2 years (972
vs. 693 ng/mL) while CL/F values were similar (14.9 and
15.6 L/h, respectively). As stated previously, Japanese
patients aged 0.5–2 years received only 15 mg dose
whatever their body weight, while Caucasian patients in the
same age range but weighing more than 10.5 kg received
30 mg dose. However, about 1/4 of the Japanese patients
aged 0.5–2 years weighted more than 10.5 kg. This could
explain the higher mean Cmax value on Caucasian patients.
No difference was seen in Cmax and CL/F values when
30 mg was administered to Japanese children aged
2–7 years and to Caucasian children aged 2–6 years (419
and 411 ng/mL, and 29.9 and 34.3 L/h, respectively).
Cmax values were 36 % higher in Caucasian than in
Japanese children aged 6 or 7–12 years (409 vs. 301 ng/
mL) with CL/F values 46 % higher in Japanese than in
Caucasian children. This difference might be explained by
the small number of Caucasian patients studied (n = 14) as
compared to Japanese children (n = 173). Moreover, while
Caucasian children were enrolled into a same single study,
Japanese patients were enrolled into several studies; the
inter-study variation could also explain such differences.
Last, Cmax and CL/F values obtained in adults were also
similar between Japanese and Caucasian patients.
Based on CL/F values, there was no major difference
between Japanese and Caucasian across adults, adolescents
and infants. Consequently, the difference observed in
Japanese children aged 6 or 7–12 years do not seem to be
explained by ethnic factors affecting metabolic or excretion
systems.
CL/F in pediatric patients was 27 % (\2 years) and
51 % (2–6/7 years) of the adult patients’ clearance.
Conclusion
The PopPK technique allowed estimating the PK of fexo-
fenadine in Japanese pediatric patients despite the very low
number of samples collected per patient.
The exposure parameters were in the same magnitude
than those observed in adults and in Caucasian patients,
except for the 30 mg BID dose given to patients aged
7–12 years.
These findings support the interest of the proposed
dosing regimens in agreement with the dosing recom-
mendations in Caucasians. These dosing regimens (twice
daily doses of: (i) 15 mg for patients aged from 6 months
up to less than 2 years, (ii) 30 mg for patients 2–11 years
of age and (iii) 60 mg for 12 years or more) allowed
obtaining adequate exposures across Caucasian and Japa-
nese population, from pediatric to adult stage.
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